| 1. |
- Aggelopoulos, Christos A., et al.
(författare)
-
Cold Atmospheric Plasma Attenuates Breast Cancer Cell Growth Through Regulation of Cell Microenvironment Effectors
- 2022
-
Ingår i: Frontiers in Oncology. - : Frontiers Media SA. - 2234-943X. ; 11
-
Tidskriftsartikel (refereegranskat)abstract
- Breast cancer exists in multiple subtypes some of which still lack a targeted and effective therapy. Cold atmospheric plasma (CAP) has been proposed as an emerging anti-cancer treatment modality. In this study, we investigated the effects of direct and indirect CAP treatment driven by the advantageous nanosecond pulsed discharge on breast cancer cells of different malignant phenotypes and estrogen receptor (ER) status, a major factor in the prognosis and therapeutic management of breast cancer. The main CAP reactive species in liquid (i.e. H2O2, NO2−/NO3−) and gas phase were determined as a function of plasma operational parameters (i.e. treatment time, pulse voltage and frequency), while pre-treatment with the ROS scavenger NAC revealed the impact of ROS in the treatment. CAP treatment induced intense phenotypic changes and apoptosis in both ER+ and ER- cells, which is associated with the mitochondrial pathway as evidenced by the increased Bax/Bcl-2 ratio and cleavage of PARP-1. Interestingly, CAP significantly reduced CD44 protein expression (a major cancer stem cell marker and matrix receptor), while differentially affected the expression of proteases and inflammatory mediators. Collectively, the findings of the present study suggest that CAP suppresses breast cancer cell growth and regulates several effectors of the tumor microenvironment and thus it could represent an efficient therapeutic approach for distinct breast cancer subtypes.
|
|
| 2. |
- Emmelmann, Marc, et al.
(författare)
-
Deliverable 6.2: Trials and experimentation (cycle 2)
- 2020
-
Rapport (refereegranskat)abstract
- This deliverable presents the second cycle of trials and experimentation activities executed over 5GENESIS facilities. The document is the continuation of deliverable D6.1, in the sense that it captures tests carried out over the evolved infrastructures hosting 5GENESIS facilities following the methodology defined in D6.1. In this document 8 main KPIs and 4 application specific validation trials achieved, under 123 experiments that performed in total. The tests focus more on i) the evolved 5G infrastructure deployments that includes radio and core elements in non-standalone (NSA) deployment configurations based on commercial and open implementations, and ii) the use of Open 5GENESIS Suite for the execution of the tests.
|
|
| 3. |
- Xylouris, Georgios, et al.
(författare)
-
Experimentation and 5G KPI measurements in the 5GENESIS platforms
- 2021
-
Ingår i: 5G-MeMU '21. - New York, NY, USA : Association for Computing Machinery (ACM). - 9781450386364 ; , s. 1-7
-
Konferensbidrag (refereegranskat)abstract
- The adoption of 5G has recently picked up pace and across the globe commercial deployments are more and more numerous. In addition to better performance, 5G brings, among others, management and operation flexibility, thus allowing industry verticals to exploit features of the telecommunication networks that go far beyond the new mobile access capabilities. As with any new technology, the integration, testing and validation of new vertical applications pose great challenges at both management and operational levels. In this context, there is an evident need for 5G infrastructure facilities that offer testing and validation capabilities through a flexible experimentation framework. This paper presents the 5GENESIS EU-funded research project Experimentation Facility and the results of the validation campaigns conducted in its five experimentation platforms. The tests and obtained results were facilitated by the 5GENESIS Suite, an open-source framework providing test automation and result analytics.
|
|
